gd2bi-aatc
mAbexperimentalMulti-specific
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2014 (NCT02173093)
Timeline
2010s
- Jan 1, 2014
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Disialoganglioside GD2Immunity, passive
Disialoganglioside GD2 immunity, passive
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- gd2bi-aatc
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02173093 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2014 | National Cancer Institute (NCI), Wayne State University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2014 |
| Wayne State University | Academic/Hospital | 1 | 1 | 1 | 2014 |
2 organizations
Page 1 / 1